# Enriqueta Felip
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/enriqueta-felip/
## Facts
| Field | Value |
| --- | --- |
| Citations | 111,423 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 129 |
| i10-index | 596 |
| Last Known Institution | Hebron University |
| OpenAlex ID | https://openalex.org/A5090324173 |
| ORCID iD | 0000-0002-7620-0098 |
| Works | 1,470 |
## Researcher papers
Showing 12 of 43.
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer](https://scholariq.org/papers/first-line-crizotinib-versus-chemotherapy-in-i-alk-i-positive-lung-cancer/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/azd9291-in-egfr-inhibitor-resistant-non-small-cell-lung-cancer/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M](https://scholariq.org/papers/acquired-egfr-c797s-mutation-mediates-resistance-to-azd9291-in-non-small-cell/)
- [Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial](https://scholariq.org/papers/adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-ib-iiia-non/)
- [Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
## Researcher university
- [Hebron University](https://scholariq.org/institutions/hebron-university/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.